Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead

Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Publicado:	2018
Materias:	active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis pathology procedures Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Nanomedicine Nanoparticles Nanotechnology Tuberculosis
Acceso en línea:	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_07248741_v35_n11_p_Grotz http://hdl.handle.net/20.500.12110/paper_07248741_v35_n11_p_Grotz
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	paper:paper_07248741_v35_n11_p_Grotz
record_format	dspace
spelling	paper:paper_07248741_v35_n11_p_Grotz2023-06-08T15:43:42Z Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nanotechnology nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics tuberculosis animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis nanotechnology pathology procedures tuberculosis Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Mycobacterium tuberculosis Nanomedicine Nanoparticles Nanotechnology Tuberculosis Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant Mycobacterium tuberculosis (Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations. © 2018, Springer Science+Business Media, LLC, part of Springer Nature. 2018 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_07248741_v35_n11_p_Grotz http://hdl.handle.net/20.500.12110/paper_07248741_v35_n11_p_Grotz
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nanotechnology nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics tuberculosis animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis nanotechnology pathology procedures tuberculosis Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Mycobacterium tuberculosis Nanomedicine Nanoparticles Nanotechnology Tuberculosis
spellingShingle	active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nanotechnology nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics tuberculosis animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis nanotechnology pathology procedures tuberculosis Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Mycobacterium tuberculosis Nanomedicine Nanoparticles Nanotechnology Tuberculosis Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
topic_facet	active targeting nanotechnology respirable nanocarriers tuberculosis liposome nanoparticle niosome tuberculostatic agent tuberculostatic agent cost disease carrier disease eradication drug delivery system drug therapy human incidence micelle nanomedicine nanotechnology nonhuman polymerization prevalence priority journal randomized controlled trial (topic) Review socioeconomics tuberculosis animal antibiotic resistance chemistry drug development drug effect Mycobacterium tuberculosis nanotechnology pathology procedures tuberculosis Animals Antitubercular Agents Drug Delivery Systems Drug Discovery Drug Resistance, Bacterial Humans Liposomes Micelles Mycobacterium tuberculosis Nanomedicine Nanoparticles Nanotechnology Tuberculosis
description	Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant Mycobacterium tuberculosis (Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
title	Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
title_short	Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
title_full	Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
title_fullStr	Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
title_full_unstemmed	Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
title_sort	nanotechnology in tuberculosis: state of the art and the challenges ahead
publishDate	2018
url	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_07248741_v35_n11_p_Grotz http://hdl.handle.net/20.500.12110/paper_07248741_v35_n11_p_Grotz
_version_	1768545561362825216

Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead

Ejemplares similares